Clinical trialNCT05705505UnknownPhase 1/PHASE2Interventional

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

SponsorTraws Pharma, Inc.Enrollment60Endometrioid Endometrial Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the safety and efficacy of increasing doses of narazaciclib (ON 123300) in combination with the standard daily dose (2.5mg) of letrozole in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer and other Gynecologic Malignancies.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Victor Moyo, MD
Onconova Therapeutics
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Arizona Oncology Associates, Pc - Hope
Tucson, Arizona, United States
Joseph Buscema, MD
Recruiting
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States
Timothy G Larson, MD
Recruiting
Perlmutter Cancer Center at Nyu Langone Hospital - Long Island
Mineola, New York, United States
Bhavana Pothuri, MD
Recruiting
Nyu Langone
New York, New York, United States
Bhavana Pothuri, MD
Recruiting
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
Charles K Anderson, MD
Recruiting
Greenville Health System, Institute for Oncology Clinical Research
Greenville, South Carolina, United States
W. Jeff Edenfield, MD
Recruiting
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Noelle G Cloven, MD
Recruiting
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, United States
Noelle G Cloven, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Letrozole 2.5mgNarazaciclib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Mar 2023
Primary completion: 31 Jan 2026
Completion: 28 Feb 2026
Last update posted: 12 Dec 2023
Registered enrollment: 60
Registry id: NCT05705505

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.